Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura : A NICE single technology appraisal
Citation
Boyers , D , Jia , X , Jenkinson , D & Mowatt , G 2012 , ' Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura : A NICE single technology appraisal ' , Pharmacoeconomics , vol. 30 , no. 6 , pp. 483-495 . https://doi.org/10.2165/11591550-000000000-00000
URI
http://hdl.handle.net/2164/2585http://www.scopus.com/inward/record.url?scp=84861070229&partnerID=8YFLogxK
Rights
This is a non-final version of an article published in final form in Boyers, D, Jia, X, Jenkinson, D & Mowatt, G 2012, 'Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: A NICE single technology appraisal', Pharmacoeconomics, vol 30, no. 6, pp. 483-495.